First Time Loading...

Bayer AG
XETRA:BAYN

Watchlist Manager
Bayer AG Logo
Bayer AG
XETRA:BAYN
Watchlist
Price: 53.42 EUR -1.71% Market Closed
Updated: May 31, 2023

Intrinsic Value

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. [ Read More ]

The intrinsic value of one BAYN stock under the Base Case scenario is 93.16 EUR. Compared to the current market price of 53.42 EUR, Bayer AG is Undervalued by 43%.

Key Points:
BAYN Intrinsic Value
Base Case
93.16 EUR
Undervaluation 43%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

Financials

Balance Sheet Decomposition
Bayer AG

Current Assets 39.6B
Cash & Short-Term Investments 8B
Receivables 18.1B
Other Current Assets 13.5B
Non-Current Assets 85.4B
Long-Term Investments 2.8B
PP&E 13.3B
Intangibles 62.6B
Other Non-Current Assets 6.7B
Current Liabilities 34.4B
Accounts Payable 6.3B
Other Current Liabilities 28.1B
Non-Current Liabilities 49.8B
Long-Term Debt 33.6B
Other Non-Current Liabilities 16.2B
Efficiency
Fundamental Scores

BAYN Profitability Score
Profitability Due Diligence

Bayer AG's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Years Revenue Growth
Positive 1-Year Revenue Growth
46/100
Profitability
Score

Bayer AG's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

BAYN Solvency Score
Solvency Due Diligence

Bayer AG's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Positive Net Debt
36/100
Solvency
Score

Bayer AG's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BAYN Price Targets Summary
Bayer AG

Wall Street analysts forecast BAYN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BAYN is 76.06 EUR with a low forecast of 57.57 EUR and a high forecast of 105 EUR.

Lowest
Price Target
57.57 EUR
8% Upside
Average
Price Target
76.06 EUR
42% Upside
Highest
Price Target
105 EUR
97% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

BAYN Competitors
Bayer AG

BAYN Suppliers & Customers
Bayer AG

Suppliers Map
Customers Map

Shareholder Return

BAYN Return Decomposition
Main factors of price return

Market capitalization of BAYN shares decreased by 23.51% over the past 5 years. The primary factor behind the change was a decrease in net margin from 19.2% to 6%, leading to a drop in the market capitalization of Bayer AG by 101.88%.

Market capitalization of BAYN shares decreased by 23.51% over the past 5 years. The primary factor behind the change was a decrease in net margin from 19.2% to 6%, leading to a drop in the market capitalization of Bayer AG by 101.88%.

-23.51%
68.6B 52.5B
Market Cap Growth
+46.9%
10.1 17.3
P/E Change
-70.41%
6.8B 3B
Earnings Growth
Market Cap Growth
-23.51%
P/E Change
+46.9%
Earnings Growth
-70.41%
What is price return decomposition?

BAYN Price
Bayer AG

1M 1M
-7%
6M 6M
+1%
1Y 1Y
-16%
3Y 3Y
-6%
5Y 5Y
-35%
10Y 10Y
-10%
Annual Price Range
53.42
52w Low
45.4256
52w High
63.9397
Price Metrics
Average Annual Return -10.54%
Standard Deviation of Annual Returns 29.98%
Max Drawdown -56%
Shares Statistics
Market Capitalization 52.5B EUR
Shares Outstanding 982 420 000
Percentage of Shares Shorted
N/A

Company Profile

Bayer AG Logo
Bayer AG

Country

Germany

Industry

Pharmaceuticals

Market Cap

52.5B EUR

Dividend Yield

0%

Description

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 99,637 full-time employees. The firm's segments are Pharmaceuticals, Consumer Health, Crop Science. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The firm is focusing on their oncology platform for Targeted Alpha Therapies for treating prostate cancer. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds.

Contact

NORDRHEIN-WESTFALEN
Leverkusen
Kaiser-Wilhelm-Allee 1
+49214301.0
https://www.bayer.de/

IPO

1997-11-28

Employees

99 637

Officers

Chairman of Management Board, CEO & Chief Sustainability Officer
Mr. Werner Baumann
CFO & Member of Management Board
Mr. Wolfgang U. Nickl
Member of Management Board & Pres of the Consumer Health Division
Mr. Heiko W. J. Schipper
Head of the Pharmaceuticals Division & Member of the Board of Management
Mr. Stefan Oelrich
Chief Transformation & Talent Officer, Labor Director and Member of Management Board
Ms. Sarena S. Lin
Member of Management Board & Pres of the Crop Science Division
Mr. Rodrigo Santos
Show More
Head of Accounting and Head of Taxes
Mr. Bernd-Peter Bier
Head of Investor Relations
Mr. Oliver Maier
Head of Law, Patents & Compliance
Dr. Gabriel Harnier
Head of Communications, Gov. Relations and Corp. Brand
Mr. Michael Preuss
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one BAYN stock?

The intrinsic value of one BAYN stock under the Base Case scenario is 93.16 EUR.

Is BAYN stock undervalued or overvalued?

Compared to the current market price of 53.42 EUR, Bayer AG is Undervalued by 43%.